Bet on the placebo

The Phase II trial of Valentis Inc.'s Deltavasc gene therapy may have missed its endpoint in treating peripheral arterial disease (PAD), but the company thinks that all is not lost. The PINC polymer carrier portion of Deltavasc may be at least as efficacious as VLTS's angiogenic Del-1 gene and may provide

Read the full 512 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE